Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

被引:8
作者
Dimitrova, Maria [1 ]
Doneva, Miglena [1 ]
Valov, Vasil [2 ]
Yordanova, Stanislava [1 ]
Manova, Manoela [1 ]
Savova, Alexandra [1 ]
Mitov, Konstantin [1 ]
Petrova, Guenka [1 ]
Petkova, Valentina [1 ]
Czech, Marcin [3 ,4 ]
机构
[1] Med Univ Sofia, Dept Social Pharm, Fac Pharm, Sofia, Bulgaria
[2] Novo Nordisk Pharma EAD, Sofia, Bulgaria
[3] Novo Nordisk Pharma Sp Zoo, Warsaw, Poland
[4] Med Univ Warsaw, Dept Pharmacoecon, Fac Pharm, Warsaw, Poland
关键词
diabetes hospitalization; microvascular complications cost; macrovascular complications cost; HEALTH-CARE COSTS; UNITED-STATES; NEPHROPATHY; MELLITUS; BURDEN;
D O I
10.1080/13102818.2015.1042912
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The objective of this study was to evaluate the cost of hospitalizations due to micro- and macrovascular complications in an observed cohort of 433 patients with diabetes. A six-month combined retrospective and prospective observational study was performed. The patients were separated into two groups depending on the type of diabetes and further into subgroups depending on the reason for hospitalization. The total costs for each subgroup were calculated and compared to the total costs of treatment for the observed period. In the type 2 diabetes group (n = 255), there were 128 people with microvascular complications and 215 ones with macrovascular complications, whereas in the type 1 diabetes group, there were only 70 people out of 178 with microvascular complications and 72 ones with macrovascular complications. The total cost of hospitalizations in the type 2 diabetes group was 34469.76 EUR with the following reported reasons for hospitalizations: poor control of diabetes (45%), microvascular complications (23%) and macrovascular complications (31%). In the type 1 diabetes group, the total hospitalizations cost was equal to 15319.33 EUR with the following split: 59% due to poor control of diabetes, 22% due to microvascular complications and 19% due to macrovascular complications. Thus, type 2 diabetes is more costly than type 1 when hospitalizations occur. Type 2 diabetes is associated with higher cost of macrovascular complications than of microvascular ones probably due to high hypertension prevalence. Costs are paid by the health insurance fund and the differences need to be systematically revealed.
引用
收藏
页码:805 / 813
页数:9
相关论文
共 28 条
[1]  
ABRASS CK, 1995, WESTERN J MED, V162, P318
[2]  
[Anonymous], 2012, DIABETES EXPENDITURE
[3]  
[Anonymous], 2011, Diabetes Atlas, V5th
[4]  
Anwer Z, 2011, EUR REV MED PHARMACO, V15, P1256
[5]   Type 2 diabetes and health care costs in Latin America: exploring the need for greater preventive medicine [J].
Arredondo, Armando .
BMC MEDICINE, 2014, 12
[6]   The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management [J].
Bjegovic, Vesna ;
Terzic, Zorica ;
Marinkovic, Jelena ;
Lalic, Nebojsa ;
Sipetic, Sandra ;
Laaser, Ulrich .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2007, 8 (02) :97-103
[7]  
Borisova A-M, 2013, PREPORAKI DOBRA KLIN
[8]   Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting [J].
Cade, W. Todd .
PHYSICAL THERAPY, 2008, 88 (11) :1322-1335
[9]   Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy [J].
Chibber, R ;
Molinatti, PA ;
Rosatto, N ;
Lambourne, B ;
Kohner, EM .
DIABETOLOGIA, 1997, 40 (02) :156-164
[10]   Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis [J].
Clarke, Philip M. ;
Glasziou, Paul ;
Patel, Anushka ;
Chalmers, John ;
Woodward, Mark ;
Harrap, Stephen B. ;
Salomon, Joshua A. .
PLOS MEDICINE, 2010, 7 (02)